Featured Image
Why is it important?
This is one of the first reports of drug resistance mutations identified against an integrase inhibitor, MK-2048, commonly known as Raltegravir (Merck). Although this mutation rendered HIV partially resistant to the drug, the virus was significantly impaired in its capacity to multiply therefore escalate HIV infection.
Perspectives
This was the first of other studies that identified new mutations against integrase inhibitors. Importantly though, since the mutations had such a detrimental effect on virus multiplication, it is still a very good treatment venue in combination with other antiretrovirals.
Tamara Bar-Magen Numhauser
University of Helsinki
Read the Original
This page is a summary of: Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor, Journal of Virology, July 2010, ASM Journals,
DOI: 10.1128/jvi.01164-10.
You can read the full text:
Contributors
The following have contributed to this page
